Abbott India
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Abbott India is currently navigating a mixed growth landscape, with management indicating a cautious sales growth target of 8-9%. The CNS therapy segment has demonstrated strong performance, while the Women's Health portfolio is recovering from previous declines, although challenges persist with key brands and regulatory pressures. Vista's financial outlook reflects stable revenue growth and margins, supported by a favorable macro environment for the pharmaceutical sector, particularly due to currency depreciation and a strong pipeline of biosimilars. However, rising input costs and increased competition present headwinds. Over the next 12-24 months, opportunities lie in expanding product offerings and potential inorganic partnerships, while execution risks and market dynamics will require close monitoring. Overall, Abbott India is positioned for disciplined growth, with a fair valuation and an expected upside of approximately 15.2%
Why We Like This Stock
- Strong performance in the CNS therapy segment supports revenue growth
- Management's focus on expanding product offerings and potential partnerships enhances long-term growth prospects
- Favorable currency depreciation is expected to boost revenues for export-oriented products
Things To Watch Out For
- Regulatory pressures and underperformance of key brands may hinder growth
- Rising input costs could pressure profit margins in the near term
- Increased competition in the domestic market may affect pricing power and market share
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 5,849 | 6,409 | 6,929 | 6,961 | 7,567 |
| Profit Before Tax (Cr.) | 1,618 | 1,888 | 2,079 | 2,116 | 2,302 |
| PBT Margin | 27.7% | 29.5% | 30.0% | 30.4% | 30.4% |
| Net Profit (Cr.) | 1,202 | 1,408 | 1,535 | 1,569 | 1,707 |
| Earnings Per Share | 565.7 | 662.8 | 722.1 | 738.5 | 803.5 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| BOB Capital Markets | ▲ Buy | 30,839 | 04-Sep-2026 |
| ICICI Securities | ▲ Buy | 32,550 | 13-Aug-2026 |
| JPMorgan | ► Hold | 27,500 | 15-Apr-2026 |
Company Overview
Show Company Profile
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, hypothyroidism, central nervous system, vaccines, and multispecialty, including insomnia, vertigo, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.